詳細検索

詳細検索

お問い合わせ

Global Poultry Live Attenuated Vaccine Market Outlook, InDepth Analysis & Forecast to 2032

Global Poultry Live Attenuated Vaccine Market Outlook, InDepth Analysis & Forecast to 2032


家禽用弱毒生ワクチンの世界市場 2026-2032年

The global Poultry Live Attenuated Vaccine market is projected to grow from US$ 1209 million in 2025 to US$ 1623 million by 2032, at a CAGR of 4.5% (2026-2032), driven by critical product segments ... もっと見る

 

 

出版社
QYResearch
QYリサーチ
出版年月
2026年11月16日
電子版価格
US$4,900
シングルユーザライセンス
ライセンス・価格情報/注文方法はこちら
納期
5-7営業日
言語
英語

英語原文をAIを使って翻訳しています。


 

お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る



図表リスト

List of Tables
Table 1. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Poultry Live Attenuated Vaccine Revenue by Region (US$ Million), 2021-2026
Table 7. Global Poultry Live Attenuated Vaccine Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Poultry Live Attenuated Vaccine Revenue by Players (US$ Million), 2021-2026
Table 10. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Poultry Live Attenuated Vaccine Revenue, 2025
Table 13. Global Poultry Live Attenuated Vaccine Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Poultry Live Attenuated Vaccine Companies Headquarters
Table 15. Global Poultry Live Attenuated Vaccine Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Poultry Live Attenuated Vaccine Revenue by Type (US$ Million), 2021-2026
Table 19. Global Poultry Live Attenuated Vaccine Revenue by Type (US$ Million), 2027-2032
Table 20. Global Poultry Live Attenuated Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026
Table 21. Global Poultry Live Attenuated Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032
Table 22. Global Poultry Live Attenuated Vaccine Revenue by Dosage Form (US$ Million), 2021-2026
Table 23. Global Poultry Live Attenuated Vaccine Revenue by Dosage Form (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Poultry Live Attenuated Vaccine Revenue by Application (US$ Million), 2021-2026
Table 26. Global Poultry Live Attenuated Vaccine Revenue by Application (US$ Million), 2027-2032
Table 27. Poultry Live Attenuated Vaccine High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers
Table 31. North America Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers
Table 33. Europe Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Poultry Live Attenuated Vaccine Investment Opportunities and Key Challenges
Table 37. Central and South America Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Poultry Live Attenuated Vaccine Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. MSD Animal Health(Merck) Corporation Information
Table 41. MSD Animal Health(Merck) Description and Major Businesses
Table 42. MSD Animal Health(Merck) Product Features and Attributes
Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025
Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025
Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025
Table 47. MSD Animal Health(Merck) Poultry Live Attenuated Vaccine SWOT Analysis
Table 48. MSD Animal Health(Merck) Recent Developments
Table 49. Zoetis Corporation Information
Table 50. Zoetis Description and Major Businesses
Table 51. Zoetis Product Features and Attributes
Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Zoetis Revenue Proportion by Product in 2025
Table 54. Zoetis Revenue Proportion by Application in 2025
Table 55. Zoetis Revenue Proportion by Geographic Area in 2025
Table 56. Zoetis Poultry Live Attenuated Vaccine SWOT Analysis
Table 57. Zoetis Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Poultry Live Attenuated Vaccine SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Poultry Live Attenuated Vaccine SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Elanco Animal Health Corporation Information
Table 77. Elanco Animal Health Description and Major Businesses
Table 78. Elanco Animal Health Product Features and Attributes
Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Elanco Animal Health Revenue Proportion by Product in 2025
Table 81. Elanco Animal Health Revenue Proportion by Application in 2025
Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025
Table 83. Elanco Animal Health Poultry Live Attenuated Vaccine SWOT Analysis
Table 84. Elanco Animal Health Recent Developments
Table 85. HIPRA Corporation Information
Table 86. HIPRA Description and Major Businesses
Table 87. HIPRA Product Features and Attributes
Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. HIPRA Recent Developments
Table 90. Vaxxinova Corporation Information
Table 91. Vaxxinova Description and Major Businesses
Table 92. Vaxxinova Product Features and Attributes
Table 93. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Vaxxinova Recent Developments
Table 95. QYH Biotech Corporation Information
Table 96. QYH Biotech Description and Major Businesses
Table 97. QYH Biotech Product Features and Attributes
Table 98. QYH Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. QYH Biotech Recent Developments
Table 100. Pulike Corporation Information
Table 101. Pulike Description and Major Businesses
Table 102. Pulike Product Features and Attributes
Table 103. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Pulike Recent Developments
Table 105. Harbin Pharmaceutical Group Corporation Information
Table 106. Harbin Pharmaceutical Group Description and Major Businesses
Table 107. Harbin Pharmaceutical Group Product Features and Attributes
Table 108. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Harbin Pharmaceutical Group Recent Developments
Table 110. Nisseiken Corporation Information
Table 111. Nisseiken Description and Major Businesses
Table 112. Nisseiken Product Features and Attributes
Table 113. Nisseiken Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Nisseiken Recent Developments
Table 115. Hester Biosciences Corporation Information
Table 116. Hester Biosciences Description and Major Businesses
Table 117. Hester Biosciences Product Features and Attributes
Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Hester Biosciences Recent Developments
Table 120. Phibro Animal Health Corporation Information
Table 121. Phibro Animal Health Description and Major Businesses
Table 122. Phibro Animal Health Product Features and Attributes
Table 123. Phibro Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Phibro Animal Health Recent Developments
Table 125. CAVAC Corporation Information
Table 126. CAVAC Description and Major Businesses
Table 127. CAVAC Product Features and Attributes
Table 128. CAVAC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. CAVAC Recent Developments
Table 130. KBNP Corporation Information
Table 131. KBNP Description and Major Businesses
Table 132. KBNP Product Features and Attributes
Table 133. KBNP Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. KBNP Recent Developments
Table 135. Bioveta Corporation Information
Table 136. Bioveta Description and Major Businesses
Table 137. Bioveta Product Features and Attributes
Table 138. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Bioveta Recent Developments
Table 140. Jilin Zhengye Corporation Information
Table 141. Jilin Zhengye Description and Major Businesses
Table 142. Jilin Zhengye Product Features and Attributes
Table 143. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Jilin Zhengye Recent Developments
Table 145. Yebio Corporation Information
Table 146. Yebio Description and Major Businesses
Table 147. Yebio Product Features and Attributes
Table 148. Yebio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Yebio Recent Developments
Table 150. Sinder Corporation Information
Table 151. Sinder Description and Major Businesses
Table 152. Sinder Product Features and Attributes
Table 153. Sinder Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Sinder Recent Developments
Table 155. Guangzhou South China Biological Medicine Corporation Information
Table 156. Guangzhou South China Biological Medicine Description and Major Businesses
Table 157. Guangzhou South China Biological Medicine Product Features and Attributes
Table 158. Guangzhou South China Biological Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Guangzhou South China Biological Medicine Recent Developments
Table 160. Technologies, Platforms and Infrastructure
Table 161. Distributors List
Table 162. Market Trends and Market Evolution
Table 163. Market Drivers and Opportunities
Table 164. Market Challenges, Risks, and Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Live Attenuated Viral Vaccines Product Picture
Figure 3. Live Attenuated Bacterial Vaccines Product Picture
Figure 4. Others Product Picture
Figure 5. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Monovalent Live Attenuated Vaccines Product Picture
Figure 7. Bivalent Live Attenuated Vaccines Product Picture
Figure 8. Multivalent Live Attenuated Vaccines Product Picture
Figure 9. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Lyophilized Live Attenuated Vaccines Product Picture
Figure 11. Frozen Live Attenuated Vaccines Product Picture
Figure 12. Liquid Live Attenuated Vaccines Product Picture
Figure 13. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 14. Broiler Farming
Figure 15. Layer Farming
Figure 16. Breeder Farming
Figure 17. Others
Figure 18. Poultry Live Attenuated Vaccine Report Years Considered
Figure 19. Global Poultry Live Attenuated Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 21. Global Poultry Live Attenuated Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share Ranking (2025)
Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 25. Live Attenuated Viral Vaccines Revenue-Based Market Share by Player in 2025
Figure 26. Live Attenuated Bacterial Vaccines Revenue-Based Market Share by Player in 2025
Figure 27. Others Revenue-Based Market Share by Player in 2025
Figure 28. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Type (2021-2032)
Figure 29. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 30. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Dosage Form (2021-2032)
Figure 31. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Application (2021-2032)
Figure 32. North America Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 33. North America Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025
Figure 34. North America Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 35. US Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 36. Canada Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 37. Mexico Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 38. Europe Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 39. Europe Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025
Figure 40. Europe Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 41. Germany Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 42. France Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 43. U.K. Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 44. Italy Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 45. Russia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 46. Asia-Pacific Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 47. Asia-Pacific Top 8 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025
Figure 48. Asia-Pacific Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 49. Indonesia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 50. Japan Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 51. South Korea Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 52. Australia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 53. India Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 54. Indonesia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 55. Vietnam Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 56. Malaysia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 57. Philippines Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 58. Singapore Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 59. Central and South America Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 60. Central and South America Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025
Figure 61. Central and South America Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 62. Brazil Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 63. Argentina Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 64. Middle East and Africa Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 65. Middle East and Africa Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025
Figure 66. Middle East and Africa Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 67. GCC Countries Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 68. Israel Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 69. Egypt Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 70. South Africa Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 71. Poultry Live Attenuated Vaccine Value Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

 

ページTOPに戻る


 

Summary

The global Poultry Live Attenuated Vaccine market is projected to grow from US$ 1209 million in 2025 to US$ 1623 million by 2032, at a CAGR of 4.5% (2026-2032), driven by critical product segments and diverse end‑use applications.

Poultry Live Attenuated Vaccines are veterinary biological products containing live viruses, bacteria, or other microorganisms whose pathogenicity has been substantially reduced through serial passage, directed selection, genetic modification, or other attenuation techniques while retaining limited replication capacity and immunogenicity. They are used to prevent infectious diseases and establish vaccination programs in broilers, layers, breeders, and other poultry. By pathogen type, the product is classified into Live Attenuated Viral Vaccines, Live Attenuated Bacterial Vaccines, and Others; by Antigen Combination, into Monovalent, Bivalent, and Multivalent Live Attenuated Vaccines; and by Dosage Form, into Lyophilized, Frozen, and Liquid Live Attenuated Vaccines. Administration commonly includes spray, drinking water, eye/nose drop, subcutaneous injection, and in-ovo vaccination. Key parameters include dose per bird, EID50, TCID50, PFU or CFU potency, attenuation stability, genetic stability, onset and duration of immunity, maternal-antibody interference, and storage requirements.

Key Findings
The average industry gross margin in 2025 is approximately 45%–65%.

Live Attenuated Viral Vaccines represent the largest segment, with lyophilized bivalent ND+IB vaccines being a representative high-volume product and typical potency of IB ≥10³ EID50/dose and ND ≥10⁶ EID50/dose.

Broiler Farming represents the largest downstream application.

MSD Animal Health, Zoetis, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health are positioned among the leading global suppliers.

Market Trends
The product is evolving from conventional single-disease and repeated farm vaccination toward bivalent/multivalent combinations, centralized hatchery immunization, lower vaccine reactions, and longer-lasting protection. Lyophilized ND, IB, and IBD attenuated vaccines remain central to mass spray and drinking-water programs, while Frozen HVT-vector technologies are increasing their share of higher-value applications. Boehringer Ingelheim now offers HVT+IBD, HVT+IBD+ND, and HVT+IBD+ILT frozen live-vector combinations, while Ceva's HVT-vector technology expresses the NDV F protein to provide long-term protection. Future technology development will focus on reducing maternal-antibody interference, minimizing respiratory reactions, extending duration of immunity, and deeper integration with automated hatchery vaccination.

Market Dynamics
Drivers
Demand for the product is primarily driven by high-density commercial poultry production, routine infectious-disease control, expansion of large hatcheries, and pressure to reduce vaccination cost per bird. Newcastle Disease and Infectious Bronchitis remain major diseases of commercial poultry; WOAH describes Newcastle Disease as globally widespread and Infectious Bronchitis as a major pathogen of commercial meat- and egg-type chickens. Live attenuated products can immunize thousands or tens of thousands of birds through spray or drinking water, making them especially suitable for short-cycle, high-throughput Broiler Farming. They can also stimulate humoral, local mucosal, and selected cellular immunity. Large poultry integrators increasingly use centralized hatchery spray, subcutaneous, or in-ovo administration to improve vaccination uniformity and reduce farm-level application errors.

Restraints
The main restraints include cold-chain sensitivity, variability in administration quality, maternal-antibody interference, and temporary reactions associated with selected attenuated strains. Lyophilized formulations must generally be used promptly after reconstitution, while chlorine or disinfectants in drinking water, spray droplet size, house temperature, and flock coverage can influence actual vaccination performance. Frozen HVT products require more demanding frozen or liquid-nitrogen logistics and hatchery handling. Certain conventional ND or IB attenuated strains may induce respiratory reactions under high-density, poorly ventilated, or secondary-infection conditions, meaning strain attenuation and vaccination timing must be matched to local disease pressure. WOAH also emphasizes that vaccination programs should consider vaccine type, flock immune status, disease status, and local field-virus infection risk.

Opportunities
Future opportunities are concentrated in Bivalent and Multivalent Live Attenuated Vaccines, single-dose hatchery immunization, Frozen live-vector technologies, and Live Attenuated Bacterial Vaccines. Bivalent ND+IB formulations provide protection against two major respiratory diseases in one administration. Zoetis offers relevant lyophilized products in 10,000-dose presentations for coarse spray or drinking-water use, demonstrating the importance of high-dose packaging and operational efficiency in mass vaccination. Frozen vector products provide a platform for integrating multiple protective antigens; Boehringer Ingelheim's HVT+IBD+ND can be administered to 18–19-day-old embryos or day-old chicks and is offered in 2,000- and 4,000-dose presentations. Live attenuated Salmonella products, region-specific strain combinations, and automated vaccination systems also provide future differentiation opportunities.

Challenges
The core challenge is maintaining attenuation safety, sufficient immunogenicity, and long-term genetic stability simultaneously. The organism must retain enough replication capacity to induce protective immunity, but insufficient attenuation can increase vaccine reactions or biosafety risks, while excessive attenuation may weaken protection. NDV and IBV also contain different genotypes or serotypes, and antigenic matching between vaccine and circulating field strains can influence protection and shedding control. WOAH requires attenuated live viruses to be produced under seed-lot systems with strict control over origin, purity, extraneous agents, and stability. Bivalent and Multivalent products add potential antigen interactions, increasing requirements for batch potency, vaccination scheduling, and field surveillance.

Industry Chain Analysis
The upstream supply chain mainly includes SPF embryonated chicken eggs, avian or other cell-culture substrates, master and working seed stocks, culture media, stabilizers, lyophilization protectants, sterile packaging, freeze dryers, bioreactors, filling equipment, and cold-chain infrastructure. Midstream activities include seed selection and attenuation, viral or bacterial propagation, harvesting, purification or clarification, potency determination, formulation, lyophilization/freezing/liquid filling, sterility testing, extraneous-agent testing, and batch release. WOAH states that attenuated IB virus is commonly propagated in the allantoic cavity of SPF embryonated chicken eggs or suitable cell cultures and that live vaccine harvest can be formulated into lyophilized or frozen presentations. Downstream demand includes Broiler Farming, Layer Farming, Breeder Farming, and Other poultry operations, together with hatcheries, veterinary distribution, spray equipment, drinking-water systems, in-ovo injectors, and frozen or liquid-nitrogen logistics. Leading suppliers also provide vaccination-program design, administration-quality auditing, and serological monitoring.

Segment Insights
By pathogen type, Live Attenuated Viral Vaccines represent the largest segment and primarily cover ND, IB, IBD, Marek's Disease, and other viral diseases, with lyophilized ND/IB vaccines representing one of the most mature commercial combinations. Zoetis' B1+Conn/Mass and LaSota+Mass products combine attenuated NDV and IBV, are offered in packages of up to 10 × 10,000 doses, and are administered through drinking water or coarse spray; WOAH confirms that live IBV can be formulated in lyophilized or frozen forms. Live Attenuated Bacterial Vaccines mainly address pathogens such as Salmonella and account for a smaller market share but offer increasing value in food-safety programs and enteric disease control in layers and breeders.

By Antigen Combination and Dosage Form, Monovalent products allow flexible targeting of individual diseases or regional strains, Bivalent products are most clearly represented by ND+IB combinations, and Multivalent products are increasingly enabled by vector platforms. Lyophilized formulations remain the mainstream conventional format because of mature transport, packaging, and mass-administration systems. Frozen formulations are concentrated in higher-value HVT, Marek's, and recombinant-vector applications; Boehringer Ingelheim explicitly lists both Frozen and Frozen Vector products administered subcutaneously or in ovo. Liquid products are used in selected bacterial and ready-to-use applications. Technology is therefore moving from repeated farm use of lyophilized Monovalent/Bivalent vaccines toward precise hatchery priming with Frozen Multivalent platforms plus risk-based field boosting.

Downstream Market Opportunities
Broiler Farming represents the largest application because flock sizes are large, production cycles are short, and early protection against ND, IB, IBD, and Marek's Disease must be established at very low cost per bird, making spray, drinking-water, and hatchery vaccination highly suitable. Layer Farming has a longer production cycle and places greater emphasis on long-duration protection and scheduled boosters, while Breeder Farming must protect the parent flock while also supporting stable maternal-antibody transfer to progeny. Boehringer Ingelheim's HVT+IBD+ND is specifically indicated for broilers, commercial layers, and breeders. Artificial intelligence is not part of the vaccine itself, but it can combine mortality, antibody titers, production performance, house-environment parameters, and regional outbreak data to optimize priming age and booster intervals and can use machine vision to monitor hatchery spray coverage and missed vaccination.

Regional Insights
Asia-Pacific is an important production and consumption region with large Broiler, Layer, and Breeder industries and substantial demand for control of ND, IB, and IBD. Market participants include QYH Biotech, Pulike, Harbin Pharmaceutical Group, Nisseiken, Hester Biosciences, Phibro Animal Health, Vaxxinova, KBNP, Jilin Zhengye, Yebio, Sinder, and Guangzhou South China Biological Medicine. North America has highly integrated hatchery and poultry-production systems, supporting mature markets for large-dose Lyophilized vaccines and automated administration. Europe has a strong technology base in recombinant vectors, hatchery immunization, and quality regulation. WOAH describes Newcastle Disease as globally widespread and Infectious Bronchitis as a worldwide disease of commercial chickens, sustaining long-term demand for cost-efficient conventional Lyophilized attenuated vaccines in Asia, Africa, and Latin America.

Competitive Landscape Analysis
The product has substantial barriers in seed technology, SPF production systems, biological manufacturing facilities, quality control, cold-chain management, and regulatory approval. Representative leading players include MSD Animal Health (Merck), Zoetis, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health. Boehringer Ingelheim's portfolio spans conventional Lyophilized IBD live vaccines, Frozen Marek's vaccines, and HVT+IBD and HVT+IBD+ND live-vector platforms. Zoetis uses established B1, LaSota, Massachusetts, and Connecticut strains across ND, IB, and combination modified-live portfolios, while Ceva combines HVT-vector technology with conventional day-one attenuated ND vaccination in integrated control programs. Competition among leading suppliers is shifting from individual strains and potency toward broader antigen combinations, Frozen vector platforms, hatchery automation, maternal-antibody compatibility, and complete vaccination-program services.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Poultry Live Attenuated Vaccine market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
MSD Animal Health(Merck)
Zoetis
Boehringer Ingelheim
Ceva Santé Animale
Elanco Animal Health
HIPRA
Vaxxinova
QYH Biotech
Pulike
Harbin Pharmaceutical Group
Nisseiken
Hester Biosciences
Phibro Animal Health
CAVAC
KBNP
Bioveta
Jilin Zhengye
Yebio
Sinder
Guangzhou South China Biological Medicine

Segment by Type
Live Attenuated Viral Vaccines
Live Attenuated Bacterial Vaccines
Others

Segment by Antigen Combination
Monovalent Live Attenuated Vaccines
Bivalent Live Attenuated Vaccines
Multivalent Live Attenuated Vaccines

Segment by Dosage Form
Lyophilized Live Attenuated Vaccines
Frozen Live Attenuated Vaccines
Liquid Live Attenuated Vaccines

Segment by Application
Broiler Farming
Layer Farming
Breeder Farming
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Poultry Live Attenuated Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る


Table of Contents

1 Study Coverage
1.1 Introduction to Poultry Live Attenuated Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Poultry Live Attenuated Vaccine Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Live Attenuated Viral Vaccines
1.2.3 Live Attenuated Bacterial Vaccines
1.2.4 Others
1.3 Market Segmentation by Antigen Combination
1.3.1 Global Poultry Live Attenuated Vaccine Market Size by Antigen Combination, 2021 vs 2025 vs 2032
1.3.2 Monovalent Live Attenuated Vaccines
1.3.3 Bivalent Live Attenuated Vaccines
1.3.4 Multivalent Live Attenuated Vaccines
1.4 Market Segmentation by Dosage Form
1.4.1 Global Poultry Live Attenuated Vaccine Market Size by Dosage Form, 2021 vs 2025 vs 2032
1.4.2 Lyophilized Live Attenuated Vaccines
1.4.3 Frozen Live Attenuated Vaccines
1.4.4 Liquid Live Attenuated Vaccines
1.5 Market Segmentation by Application
1.5.1 Global Poultry Live Attenuated Vaccine Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Broiler Farming
1.5.3 Layer Farming
1.5.4 Breeder Farming
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Poultry Live Attenuated Vaccine Revenue Estimates and Forecasts (2021-2032)
2.2 Global Poultry Live Attenuated Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Poultry Live Attenuated Vaccine Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Poultry Live Attenuated Vaccine Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Live Attenuated Viral Vaccines: Market Share by Key Players
3.3.2 Live Attenuated Bacterial Vaccines: Market Share by Key Players
3.3.3 Others: Market Share by Key Players
3.4 Global Poultry Live Attenuated Vaccine Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Poultry Live Attenuated Vaccine Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Poultry Live Attenuated Vaccine Market by Antigen Combination
4.2.1 Global Revenue by Antigen Combination (2021-2032)
4.2.2 Global Revenue-Based Market Share by Antigen Combination (2021-2032)
4.3 Global Poultry Live Attenuated Vaccine Market by Dosage Form
4.3.1 Global Revenue by Dosage Form (2021-2032)
4.3.2 Global Revenue-Based Market Share by Dosage Form (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Poultry Live Attenuated Vaccine Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Poultry Live Attenuated Vaccine Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Poultry Live Attenuated Vaccine Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Poultry Live Attenuated Vaccine Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Poultry Live Attenuated Vaccine Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Poultry Live Attenuated Vaccine Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Poultry Live Attenuated Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Poultry Live Attenuated Vaccine Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Poultry Live Attenuated Vaccine Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Poultry Live Attenuated Vaccine Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Poultry Live Attenuated Vaccine Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 MSD Animal Health(Merck)
11.1.1 MSD Animal Health(Merck) Corporation Information
11.1.2 MSD Animal Health(Merck) Business Overview
11.1.3 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine Product Features and Attributes
11.1.4 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.1.5 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine Revenue by Product in 2025
11.1.6 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine Revenue by Application in 2025
11.1.7 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine Revenue by Geographic Area in 2025
11.1.8 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine SWOT Analysis
11.1.9 MSD Animal Health(Merck) Recent Developments
11.2 Zoetis
11.2.1 Zoetis Corporation Information
11.2.2 Zoetis Business Overview
11.2.3 Zoetis Poultry Live Attenuated Vaccine Product Features and Attributes
11.2.4 Zoetis Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.2.5 Zoetis Poultry Live Attenuated Vaccine Revenue by Product in 2025
11.2.6 Zoetis Poultry Live Attenuated Vaccine Revenue by Application in 2025
11.2.7 Zoetis Poultry Live Attenuated Vaccine Revenue by Geographic Area in 2025
11.2.8 Zoetis Poultry Live Attenuated Vaccine SWOT Analysis
11.2.9 Zoetis Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Poultry Live Attenuated Vaccine Product Features and Attributes
11.3.4 Boehringer Ingelheim Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.3.5 Boehringer Ingelheim Poultry Live Attenuated Vaccine Revenue by Product in 2025
11.3.6 Boehringer Ingelheim Poultry Live Attenuated Vaccine Revenue by Application in 2025
11.3.7 Boehringer Ingelheim Poultry Live Attenuated Vaccine Revenue by Geographic Area in 2025
11.3.8 Boehringer Ingelheim Poultry Live Attenuated Vaccine SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 Ceva Santé Animale
11.4.1 Ceva Santé Animale Corporation Information
11.4.2 Ceva Santé Animale Business Overview
11.4.3 Ceva Santé Animale Poultry Live Attenuated Vaccine Product Features and Attributes
11.4.4 Ceva Santé Animale Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.4.5 Ceva Santé Animale Poultry Live Attenuated Vaccine Revenue by Product in 2025
11.4.6 Ceva Santé Animale Poultry Live Attenuated Vaccine Revenue by Application in 2025
11.4.7 Ceva Santé Animale Poultry Live Attenuated Vaccine Revenue by Geographic Area in 2025
11.4.8 Ceva Santé Animale Poultry Live Attenuated Vaccine SWOT Analysis
11.4.9 Ceva Santé Animale Recent Developments
11.5 Elanco Animal Health
11.5.1 Elanco Animal Health Corporation Information
11.5.2 Elanco Animal Health Business Overview
11.5.3 Elanco Animal Health Poultry Live Attenuated Vaccine Product Features and Attributes
11.5.4 Elanco Animal Health Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.5.5 Elanco Animal Health Poultry Live Attenuated Vaccine Revenue by Product in 2025
11.5.6 Elanco Animal Health Poultry Live Attenuated Vaccine Revenue by Application in 2025
11.5.7 Elanco Animal Health Poultry Live Attenuated Vaccine Revenue by Geographic Area in 2025
11.5.8 Elanco Animal Health Poultry Live Attenuated Vaccine SWOT Analysis
11.5.9 Elanco Animal Health Recent Developments
11.6 HIPRA
11.6.1 HIPRA Corporation Information
11.6.2 HIPRA Business Overview
11.6.3 HIPRA Poultry Live Attenuated Vaccine Product Features and Attributes
11.6.4 HIPRA Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.6.5 HIPRA Recent Developments
11.7 Vaxxinova
11.7.1 Vaxxinova Corporation Information
11.7.2 Vaxxinova Business Overview
11.7.3 Vaxxinova Poultry Live Attenuated Vaccine Product Features and Attributes
11.7.4 Vaxxinova Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.7.5 Vaxxinova Recent Developments
11.8 QYH Biotech
11.8.1 QYH Biotech Corporation Information
11.8.2 QYH Biotech Business Overview
11.8.3 QYH Biotech Poultry Live Attenuated Vaccine Product Features and Attributes
11.8.4 QYH Biotech Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.8.5 QYH Biotech Recent Developments
11.9 Pulike
11.9.1 Pulike Corporation Information
11.9.2 Pulike Business Overview
11.9.3 Pulike Poultry Live Attenuated Vaccine Product Features and Attributes
11.9.4 Pulike Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.9.5 Pulike Recent Developments
11.10 Harbin Pharmaceutical Group
11.10.1 Harbin Pharmaceutical Group Corporation Information
11.10.2 Harbin Pharmaceutical Group Business Overview
11.10.3 Harbin Pharmaceutical Group Poultry Live Attenuated Vaccine Product Features and Attributes
11.10.4 Harbin Pharmaceutical Group Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Nisseiken
11.11.1 Nisseiken Corporation Information
11.11.2 Nisseiken Business Overview
11.11.3 Nisseiken Poultry Live Attenuated Vaccine Product Features and Attributes
11.11.4 Nisseiken Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.11.5 Nisseiken Recent Developments
11.12 Hester Biosciences
11.12.1 Hester Biosciences Corporation Information
11.12.2 Hester Biosciences Business Overview
11.12.3 Hester Biosciences Poultry Live Attenuated Vaccine Product Features and Attributes
11.12.4 Hester Biosciences Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.12.5 Hester Biosciences Recent Developments
11.13 Phibro Animal Health
11.13.1 Phibro Animal Health Corporation Information
11.13.2 Phibro Animal Health Business Overview
11.13.3 Phibro Animal Health Poultry Live Attenuated Vaccine Product Features and Attributes
11.13.4 Phibro Animal Health Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.13.5 Phibro Animal Health Recent Developments
11.14 CAVAC
11.14.1 CAVAC Corporation Information
11.14.2 CAVAC Business Overview
11.14.3 CAVAC Poultry Live Attenuated Vaccine Product Features and Attributes
11.14.4 CAVAC Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.14.5 CAVAC Recent Developments
11.15 KBNP
11.15.1 KBNP Corporation Information
11.15.2 KBNP Business Overview
11.15.3 KBNP Poultry Live Attenuated Vaccine Product Features and Attributes
11.15.4 KBNP Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.15.5 KBNP Recent Developments
11.16 Bioveta
11.16.1 Bioveta Corporation Information
11.16.2 Bioveta Business Overview
11.16.3 Bioveta Poultry Live Attenuated Vaccine Product Features and Attributes
11.16.4 Bioveta Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.16.5 Bioveta Recent Developments
11.17 Jilin Zhengye
11.17.1 Jilin Zhengye Corporation Information
11.17.2 Jilin Zhengye Business Overview
11.17.3 Jilin Zhengye Poultry Live Attenuated Vaccine Product Features and Attributes
11.17.4 Jilin Zhengye Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.17.5 Jilin Zhengye Recent Developments
11.18 Yebio
11.18.1 Yebio Corporation Information
11.18.2 Yebio Business Overview
11.18.3 Yebio Poultry Live Attenuated Vaccine Product Features and Attributes
11.18.4 Yebio Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.18.5 Yebio Recent Developments
11.19 Sinder
11.19.1 Sinder Corporation Information
11.19.2 Sinder Business Overview
11.19.3 Sinder Poultry Live Attenuated Vaccine Product Features and Attributes
11.19.4 Sinder Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.19.5 Sinder Recent Developments
11.20 Guangzhou South China Biological Medicine
11.20.1 Guangzhou South China Biological Medicine Corporation Information
11.20.2 Guangzhou South China Biological Medicine Business Overview
11.20.3 Guangzhou South China Biological Medicine Poultry Live Attenuated Vaccine Product Features and Attributes
11.20.4 Guangzhou South China Biological Medicine Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026)
11.20.5 Guangzhou South China Biological Medicine Recent Developments

12 Poultry Live Attenuated Vaccine Value Chain and Ecosystem Analysis
12.1 Poultry Live Attenuated Vaccine Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Poultry Live Attenuated Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Poultry Live Attenuated Vaccine Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Poultry Live Attenuated Vaccine Revenue by Region (US$ Million), 2021-2026
Table 7. Global Poultry Live Attenuated Vaccine Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Poultry Live Attenuated Vaccine Revenue by Players (US$ Million), 2021-2026
Table 10. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Poultry Live Attenuated Vaccine Revenue, 2025
Table 13. Global Poultry Live Attenuated Vaccine Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Poultry Live Attenuated Vaccine Companies Headquarters
Table 15. Global Poultry Live Attenuated Vaccine Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Poultry Live Attenuated Vaccine Revenue by Type (US$ Million), 2021-2026
Table 19. Global Poultry Live Attenuated Vaccine Revenue by Type (US$ Million), 2027-2032
Table 20. Global Poultry Live Attenuated Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026
Table 21. Global Poultry Live Attenuated Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032
Table 22. Global Poultry Live Attenuated Vaccine Revenue by Dosage Form (US$ Million), 2021-2026
Table 23. Global Poultry Live Attenuated Vaccine Revenue by Dosage Form (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Poultry Live Attenuated Vaccine Revenue by Application (US$ Million), 2021-2026
Table 26. Global Poultry Live Attenuated Vaccine Revenue by Application (US$ Million), 2027-2032
Table 27. Poultry Live Attenuated Vaccine High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers
Table 31. North America Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers
Table 33. Europe Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Poultry Live Attenuated Vaccine Investment Opportunities and Key Challenges
Table 37. Central and South America Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Poultry Live Attenuated Vaccine Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. MSD Animal Health(Merck) Corporation Information
Table 41. MSD Animal Health(Merck) Description and Major Businesses
Table 42. MSD Animal Health(Merck) Product Features and Attributes
Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025
Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025
Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025
Table 47. MSD Animal Health(Merck) Poultry Live Attenuated Vaccine SWOT Analysis
Table 48. MSD Animal Health(Merck) Recent Developments
Table 49. Zoetis Corporation Information
Table 50. Zoetis Description and Major Businesses
Table 51. Zoetis Product Features and Attributes
Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Zoetis Revenue Proportion by Product in 2025
Table 54. Zoetis Revenue Proportion by Application in 2025
Table 55. Zoetis Revenue Proportion by Geographic Area in 2025
Table 56. Zoetis Poultry Live Attenuated Vaccine SWOT Analysis
Table 57. Zoetis Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Poultry Live Attenuated Vaccine SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Poultry Live Attenuated Vaccine SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Elanco Animal Health Corporation Information
Table 77. Elanco Animal Health Description and Major Businesses
Table 78. Elanco Animal Health Product Features and Attributes
Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Elanco Animal Health Revenue Proportion by Product in 2025
Table 81. Elanco Animal Health Revenue Proportion by Application in 2025
Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025
Table 83. Elanco Animal Health Poultry Live Attenuated Vaccine SWOT Analysis
Table 84. Elanco Animal Health Recent Developments
Table 85. HIPRA Corporation Information
Table 86. HIPRA Description and Major Businesses
Table 87. HIPRA Product Features and Attributes
Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. HIPRA Recent Developments
Table 90. Vaxxinova Corporation Information
Table 91. Vaxxinova Description and Major Businesses
Table 92. Vaxxinova Product Features and Attributes
Table 93. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Vaxxinova Recent Developments
Table 95. QYH Biotech Corporation Information
Table 96. QYH Biotech Description and Major Businesses
Table 97. QYH Biotech Product Features and Attributes
Table 98. QYH Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. QYH Biotech Recent Developments
Table 100. Pulike Corporation Information
Table 101. Pulike Description and Major Businesses
Table 102. Pulike Product Features and Attributes
Table 103. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Pulike Recent Developments
Table 105. Harbin Pharmaceutical Group Corporation Information
Table 106. Harbin Pharmaceutical Group Description and Major Businesses
Table 107. Harbin Pharmaceutical Group Product Features and Attributes
Table 108. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Harbin Pharmaceutical Group Recent Developments
Table 110. Nisseiken Corporation Information
Table 111. Nisseiken Description and Major Businesses
Table 112. Nisseiken Product Features and Attributes
Table 113. Nisseiken Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Nisseiken Recent Developments
Table 115. Hester Biosciences Corporation Information
Table 116. Hester Biosciences Description and Major Businesses
Table 117. Hester Biosciences Product Features and Attributes
Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Hester Biosciences Recent Developments
Table 120. Phibro Animal Health Corporation Information
Table 121. Phibro Animal Health Description and Major Businesses
Table 122. Phibro Animal Health Product Features and Attributes
Table 123. Phibro Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Phibro Animal Health Recent Developments
Table 125. CAVAC Corporation Information
Table 126. CAVAC Description and Major Businesses
Table 127. CAVAC Product Features and Attributes
Table 128. CAVAC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. CAVAC Recent Developments
Table 130. KBNP Corporation Information
Table 131. KBNP Description and Major Businesses
Table 132. KBNP Product Features and Attributes
Table 133. KBNP Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. KBNP Recent Developments
Table 135. Bioveta Corporation Information
Table 136. Bioveta Description and Major Businesses
Table 137. Bioveta Product Features and Attributes
Table 138. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Bioveta Recent Developments
Table 140. Jilin Zhengye Corporation Information
Table 141. Jilin Zhengye Description and Major Businesses
Table 142. Jilin Zhengye Product Features and Attributes
Table 143. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Jilin Zhengye Recent Developments
Table 145. Yebio Corporation Information
Table 146. Yebio Description and Major Businesses
Table 147. Yebio Product Features and Attributes
Table 148. Yebio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Yebio Recent Developments
Table 150. Sinder Corporation Information
Table 151. Sinder Description and Major Businesses
Table 152. Sinder Product Features and Attributes
Table 153. Sinder Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Sinder Recent Developments
Table 155. Guangzhou South China Biological Medicine Corporation Information
Table 156. Guangzhou South China Biological Medicine Description and Major Businesses
Table 157. Guangzhou South China Biological Medicine Product Features and Attributes
Table 158. Guangzhou South China Biological Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Guangzhou South China Biological Medicine Recent Developments
Table 160. Technologies, Platforms and Infrastructure
Table 161. Distributors List
Table 162. Market Trends and Market Evolution
Table 163. Market Drivers and Opportunities
Table 164. Market Challenges, Risks, and Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Live Attenuated Viral Vaccines Product Picture
Figure 3. Live Attenuated Bacterial Vaccines Product Picture
Figure 4. Others Product Picture
Figure 5. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Monovalent Live Attenuated Vaccines Product Picture
Figure 7. Bivalent Live Attenuated Vaccines Product Picture
Figure 8. Multivalent Live Attenuated Vaccines Product Picture
Figure 9. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Lyophilized Live Attenuated Vaccines Product Picture
Figure 11. Frozen Live Attenuated Vaccines Product Picture
Figure 12. Liquid Live Attenuated Vaccines Product Picture
Figure 13. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 14. Broiler Farming
Figure 15. Layer Farming
Figure 16. Breeder Farming
Figure 17. Others
Figure 18. Poultry Live Attenuated Vaccine Report Years Considered
Figure 19. Global Poultry Live Attenuated Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 21. Global Poultry Live Attenuated Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share Ranking (2025)
Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 25. Live Attenuated Viral Vaccines Revenue-Based Market Share by Player in 2025
Figure 26. Live Attenuated Bacterial Vaccines Revenue-Based Market Share by Player in 2025
Figure 27. Others Revenue-Based Market Share by Player in 2025
Figure 28. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Type (2021-2032)
Figure 29. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 30. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Dosage Form (2021-2032)
Figure 31. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Application (2021-2032)
Figure 32. North America Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 33. North America Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025
Figure 34. North America Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 35. US Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 36. Canada Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 37. Mexico Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 38. Europe Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 39. Europe Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025
Figure 40. Europe Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 41. Germany Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 42. France Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 43. U.K. Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 44. Italy Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 45. Russia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 46. Asia-Pacific Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 47. Asia-Pacific Top 8 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025
Figure 48. Asia-Pacific Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 49. Indonesia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 50. Japan Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 51. South Korea Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 52. Australia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 53. India Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 54. Indonesia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 55. Vietnam Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 56. Malaysia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 57. Philippines Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 58. Singapore Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 59. Central and South America Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 60. Central and South America Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025
Figure 61. Central and South America Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 62. Brazil Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 63. Argentina Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 64. Middle East and Africa Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 65. Middle East and Africa Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025
Figure 66. Middle East and Africa Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 67. GCC Countries Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 68. Israel Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 69. Egypt Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 70. South Africa Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032
Figure 71. Poultry Live Attenuated Vaccine Value Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/20 10:25

160.51 円

176.53 円

212.83 円

ページTOPに戻る